Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Short Interest Update

Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) saw a significant drop in short interest during the month of December. As of December 15th, there was short interest totaling 25,588 shares, a drop of 23.5% from the November 30th total of 33,462 shares. Based on an average daily volume of 3,281,479 shares, the short-interest ratio is presently 0.0 days. Currently, 0.2% of the company’s stock are short sold. Currently, 0.2% of the company’s stock are short sold. Based on an average daily volume of 3,281,479 shares, the short-interest ratio is presently 0.0 days.

Institutional Trading of Radiopharm Theranostics

A hedge fund recently raised its stake in Radiopharm Theranostics stock. PNC Financial Services Group Inc. boosted its stake in Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) by 100.0% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 16,000 shares of the company’s stock after buying an additional 8,000 shares during the period. PNC Financial Services Group Inc. owned approximately 0.20% of Radiopharm Theranostics worth $88,000 as of its most recent filing with the SEC.

Radiopharm Theranostics Price Performance

NASDAQ RADX traded up $0.06 during trading on Wednesday, reaching $5.22. 45,753 shares of the company’s stock were exchanged, compared to its average volume of 246,425. Radiopharm Theranostics has a fifty-two week low of $3.50 and a fifty-two week high of $16.25. The business has a 50 day moving average price of $4.99 and a 200-day moving average price of $5.27.

Analysts Set New Price Targets

RADX has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Radiopharm Theranostics in a research report on Wednesday, October 8th. B. Riley reiterated a “buy” rating and set a $16.00 target price (up previously from $13.00) on shares of Radiopharm Theranostics in a report on Tuesday, December 16th. Two research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Radiopharm Theranostics has a consensus rating of “Buy” and an average price target of $15.33.

Radiopharm Theranostics Company Profile

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.